Valemetostat tosylate
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Valemetostat tosylate
- Molecular weight
- 660.23
- Structure (SMILES)
- Cc1cc(C)c(CNC(=O)c2cc(Cl)c3c(c2C)O[C@@](C)([C@H]2CC[C@H](N(C)C)CC2)O3)c(=O)[nH]1.Cc1ccc(S(=O)(=O)O)cc1
- valemetostat tosilate
- Valemetostat tosilate
- VALEMETOSTAT TOSILATE [JAN]
- Valemetostat tosilate [WHO-DD]
- valemetostat tosilate jan
- valemetostat tosilate who dd
- valemetostat tosylate
- Valemetostat tosylate
- CAS registry numbers
- 1809336-93-3
- ChEMBL ID
- CHEMBL4594405
- InChIKey
- JSBKGJUYSLVFPF-WJQUPPJOSA-N
- FDA ingredient codes (UNII)
- 6N79I7X5II
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -stat
- Condition
- Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Leukemia-Lymphoma, Adult T-Cell
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0019471
- Subject identifier
- D015459
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000430
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004952
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005086
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015667
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015759
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018874
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018876
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018906
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019471
- Condition identifier
- MONDO_0019471
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0040679
- Highest recorded phase
- 1
- NCT04102150
- NCT04842877
- NCT06244485
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 83.66
- Calculated partition coefficient (ALogP)
- 4.49
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 45
- Molecular formula
- C33H42ClN3O7S
- Natural product
- No
Related records
Trials (8)
- A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
- A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
- Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
- Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)
- Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
- Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
In development for (17)
- Acute lymphoblastic leukemia Phase 1
- Acute myeloid leukemia Phase 1
- Acute myeloid leukemia by FAB classification Phase 1
- Adult T-cell leukemia/lymphoma Phase 2
- B-cell non-Hodgkin lymphoma Phase 2
- Follicular lymphoma Phase 2
- Hepatocellular carcinoma Phase 1
- Hodgkins lymphoma Phase 2
- Lymphoma Phase 2
- Mantle cell lymphoma Phase 2
- Mature T-cell and NK-cell non-Hodgkin lymphoma Phase 2
- Neoplasm Phase 1
- Non-small cell lung carcinoma Phase 1
- Prostate cancer Phase 2
- Renal cell carcinoma Phase 1
- Small cell lung carcinoma Phase 1
- Urothelial carcinoma Phase 1